Related Experiment Video
Updated: Jun 17, 2026
Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles
Published on: September 18, 2018
Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus
Kushal Vanamala1, Ketki Bhise1, Hiram Sanchez2
1Use-Inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA), commonly called a superbug, is a highly alarming antibiotic-resistant population of Staphylococcus aureus (S. aureus) bacteria. Vancomycin (VAN) was first approved by the FDA in 1988, and it is still regarded as the treatment of choice for MRSA. The efficacy of VAN treatment has become less effective due to the development of VAN resistance in MRSA and the potential for nephrotoxicity. This study aims to improve the efficacy of VAN treatment by identifying the folate receptor for MRSA infected tissues and developing folate decorated lipid nanoparticles containing VAN (LVAN). In comparison to conventional VAN, LVAN showed a higher bactericidal effect and a superior ability to inhibit biofilm in MRSA with an enhanced accumulation in MRSA infected thigh tissues and a reduced accumulation in kidney. The results suggested that LVAN is a promising candidate to overcome the current limitations of bacterial resistance and adverse side effects in kidneys found in VAN.
Insights
New folate-decorated lipid nanoparticles (LVAN) show improved efficacy against Methicillin-resistant Staphylococcus aureus (MRSA) superbugs. LVAN reduces kidney toxicity and enhances treatment for antibiotic-resistant infections.
Area of Science:
- Pharmacology
- Nanotechnology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health threat due to antibiotic resistance.
- Vancomycin (VAN) is a primary treatment for MRSA but faces challenges from emerging resistance and nephrotoxicity.
- Targeted drug delivery systems are needed to improve VAN efficacy and reduce side effects.
Purpose of the Study:
- To develop folate-decorated lipid nanoparticles (LVAN) for targeted delivery of Vancomycin (VAN) to MRSA-infected tissues.
- To evaluate the efficacy of LVAN against MRSA in vitro and in vivo.
- To assess the biodistribution and kidney accumulation of LVAN compared to conventional VAN.
Main Methods:
- Synthesis and characterization of folate-decorated lipid nanoparticles encapsulating VAN (LVAN).
- In vitro assessment of bactericidal activity and biofilm inhibition against MRSA.
- In vivo studies in MRSA-infected mouse models to evaluate therapeutic efficacy and kidney accumulation.
Main Results:
- LVAN demonstrated significantly higher bactericidal activity and superior biofilm inhibition compared to conventional VAN.
- Enhanced accumulation of LVAN was observed in MRSA-infected thigh tissues.
- LVAN exhibited reduced accumulation in the kidneys, indicating lower nephrotoxicity potential.
Conclusions:
- LVAN represents a promising nanotechnology-based approach to enhance VAN efficacy against MRSA.
- Targeted delivery via folate decoration can overcome VAN resistance and mitigate kidney-related adverse effects.
- LVAN holds potential as an improved therapeutic strategy for treating challenging MRSA infections.
